Key Takeaways
- Flat sales, sharply higher profits: Revenue was broadly flat as NLEM price cuts weighed on the top line, but a ~10% reduction in the OpEx base (roughly ₹50 cr) lifted operating profit margins by 4–5 percentage points year-on-year across all three quarters of 2023.
- NLEM margin risk neutralized: The steep price reduction on Lantus was offset by renegotiating the product’s purchase price from the parent, preserving profit margins on a percentage basis even as the full NLEM impact hit the P&L.
- Demerger on track for mid-2024: The consumer healthcare separation has cleared board, SEBI and NCLT filing milestones; a shareholder meeting is set for December 18, 2023, and management expects to execute the split by May 2024.
- Growth pipeline is a 2025 story: Multiple launches are lined up from H2 2023 through early 2025, including Soliqua (entry into the premix insulin segment) and the Allegra consumer range, but pharmaceutical innovation lead times mean the growth impact will take time to materialize.
- What to watch next quarter: Whether the volume uplift from NLEM price cuts begins to show in the sales trajectory, progress on the partnership study for extending brand reach, and any concrete inorganic moves.
Profitability: Efficiency Over Revenue
- OpEx base structurally reset: Efficiency gains across sales and marketing layers, span, and G&A have delivered a ~10% improvement in the total OpEx base, equivalent to roughly ₹50 cr in savings, which management flagged as a year-to-date achievement rather than a one-quarter event.
- Margin expansion consistent, not lumpy: Operating profit as a percentage of sales grew by almost 4–5% quarter versus the previous year across all three quarters of 2023, confirming the cost reset is durable and not an isolated Q3 outcome.
- Consumer healthcare carries higher margins: The consumer business runs at margins roughly 8–10 percentage points above the blended ~30% corporate margin, while the pharma business is lower-margin due to its imported component, a mix that will matter more once the two entities are separated.
- NLEM margin defence worked: The company secured a relook at the purchase price of Lantus from the group, which maintained profit margins on a percentage basis despite the full NLEM price reduction being absorbed in Q3.
Vaibhav Karandikar: "In the year-to-date, we have made an improvement in our OpEx base that is close to 10% of the total OpEx base. So we have become more efficient in our expenses to the tune of 10% of our base of expenses, representing something like 50 crores of improvements in efficiencies."
Demerger: Consumer Healthcare Separation
- Timeline is holding: The board approved the demerger on May 10, 2023; filings with the stock exchange and SEBI were completed by end of August; the NCLT filing followed in early October; a court order for the shareholder and creditor meeting was issued November 10, with the meeting scheduled for December 18, 2023. NCLT approval and subsequent listing are expected by mid-2024.
- Business already runs independently: Since the beginning of the year, the consumer healthcare business has operated with dedicated resources inside Sanofi India Limited, a preparatory step for the eventual legal separation.
- Post-separation strategy taking shape: Management is doubling down on the Allegra franchise, deepening consumer understanding, and working to improve India’s underdeveloped policy and regulatory framework for consumer healthcare, where most products sold as OTC globally remain prescription-only in India.
Rodolfo Hrosz: "We continue to be on track with that timeline and expect to be able to execute by May 2024, as it was the case from the beginning of the project."
Growth Pipeline: Launches and Reach
- Launch calendar spans 18 months: Frisium suspension launched in October 2023; Sanoxaban and Carmada are planned for December 2023; Soliqua, Insutage and Cetapine are slated for early 2024; AllegraM and AllegraD are planned for 2025 and beyond.
- Soliqua opens the premix segment: Soliqua, described as a very innovative product, will allow Sanofi to enter the premix insulin segment where it does not currently compete, broadening its diabetes portfolio beyond basal insulins.
- TZIELD could reshape the type-1 diabetes story: The group’s acquisition of Provention Bio brought TZIELD, the first FDA-approved treatment that delays the onset of type-1 diabetes, already commercialized in the US; management sees potential to bring it to India down the road.
- Doctor reach expanded without adding reps: The reorganization from eight business units to three, combined with a newly deployed trade organization, expanded reach by 30,000 doctors from the beginning of the year to date, mostly in tier-1 cities, using the same sales force base of roughly 1,500 representatives.
- Partnership study could extend brand reach: The company is studying partnerships with other pharma companies in India to extend the reach of its more established brands; if conclusions are positive, management expects to communicate decisions in the coming months or quarters.
- No plans for Insulin Aspart: Management gave an explicit “no” when asked about launching Insulin Aspart in India, drawing a clear boundary around the insulin portfolio.
Rodolfo Hrosz: "As you may know, as of today, there is no treatment for this diseases, diabetes type-1. And TZIELD product that belongs to the organisation that we just acquired, is the first treatment for diabetes type-1, and it delays the onset of diabetes type-1, and has already been approved by the FDA, and is already being commercialised in the US."
NLEM Impact: Price Headwinds, Volume Tailwinds
- Multiple products affected: The NLEM price reduction applies to Lantus, Amaryl, Cardace and Clexane, creating a broad-based sales headwind that explains the muted topline growth.
- Volume offset expected, not yet visible: Management expects the price reduction to lead to a significant increase in volume over time, which it believes will end up being positive for Sanofi India overall, though the timing and magnitude of that volume response remain unquantified.
- Toujeo not cannibalizing Lantus: Toujeo was launched three years ago and is growing very fast, but management does not believe any substitution effect is a material factor today; the two products are promoted simultaneously across all geographies to different patient groups based on clinical differences.
Operating Model: Reorganization and Digital Bets
- From eight business units to three: The reorganization created a more customer-centric structure, and the company deployed a full-fledged trade organization in India that did not previously exist, engaging distributors, retail chains, hospitals and institutions.
- Four digital marketing pilots underway: Management believes these pilots can have a positive impact as they advance, though no specifics on scale or timeline were provided.
- Sales force steady, not growing: The current strength of roughly 1,500 representatives (1,000 for diabetes) is considered adequate; no significant expansion is planned, though some adjustments may accompany specific launches.
- Inorganic appetite is real but unspecific: Management is constantly looking for organic and inorganic opportunities and will be ready to move if the right one appears, but offered no criteria, target segments or timeline.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Demerger execution | NCLT approval and subsequent listing of the separated consumer healthcare entity | By May 2024 |
| Product launches | Sanoxaban and Carmada (Dec 2023); Soliqua, Insutage, Cetapine (early 2024); AllegraM, AllegraD (2025 and beyond) | H2 2023 through 2025 |
| Partnership decision | Communicate conclusions from the study on pharma partnerships for brand reach extension | Coming months or quarters, if conclusions are positive |
| Sales force size | No significant increase planned; minor adjustments possible with specific launches | Ongoing |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue growth | 2% YoY |
| Domestic sales growth | Largely flat YoY |
| Domestic retained business growth (ex-Soframycin and Lantus impact) | ~4% YoY |
| Domestic growth excluding all NLEM impact | ~5.5% YoY |
| Profit before tax growth | 15% YoY |
| Operating profit growth (year-to-date) | 16% YoY |
| Operating profit margin expansion | 4-5% quarter versus previous year |
| Blended operating profit margin | ~30% |
| Consumer healthcare margin premium over blended | ~8% to 10% above blended margins |
| OpEx efficiency savings (year-to-date) | ~₹50 cr, close to 10% of total OpEx base |
| Sales force strength | 1,500 overall, 1,000 for diabetes |
| Doctor reach expansion (year-to-date) | 30,000 additional doctors |
| Demerger expected completion | Mid-2024, shareholder and creditors meeting scheduled December 18, 2023 |